Update on Monoclonal Gammopathies Affecting the Kidneys
Author Information
Author(s): Netti Giuseppe Stefano, Troise Dario, Rossini Michele, Catalano Valeria, De Luca Federica, Khalid Javeria, Camporeale Valentina, Ritrovato Fabiana, Infante Barbara, Sanguedolce Francesca, Stallone Giovanni, Ranieri Elena, Tsuji Kenji
Primary Institution: University of Foggia
Hypothesis
Monoclonal gammopathy of renal significance (MGRS) encompasses renal disorders caused by monoclonal immunoglobulins that do not meet the criteria for multiple myeloma or other malignancies.
Conclusion
The correct classification of MGRS has improved understanding and treatment of related kidney diseases.
Supporting Evidence
- Monoclonal gammopathy of renal significance (MGRS) is associated with significant morbidity due to renal lesions.
- Early recognition and treatment can improve outcomes for patients with MGRS.
- Kidney biopsy is essential for diagnosing specific lesions associated with MGRS.
Takeaway
Some people have kidney problems because of special proteins in their blood, and doctors are learning how to help them better.
Methodology
The study reviews the pathogenesis, clinical features, diagnosis, and treatment of MGRS-related kidney diseases.
Limitations
The study does not provide new data but reviews existing literature.
Participant Demographics
MGRS is mostly observed in patients over 50 years of age.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website